Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Cancel Anytime
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Judy Jideonwo holds her vaccination card after receiving a dose of the Moderna COVID-19 vaccine on April 7, 2021, at Harborview Medical Center in Seattle.

Ted S. Warren/The Associated Press

A study by researchers at the University of Oxford has found that the risk of developing rare blood clots is eight to 10 times higher in people with COVID-19 than in those who have been vaccinated.

The study of more than 500,000 infected people in the United States calculated that the blood clots, known as cerebral venous sinus thrombosis, occurred in 39 out of one million patients with COVID-19. That compares with five in one million for people who received the Oxford-AstraZeneca vaccine and four in one million for those who got the Pfizer-BioNTech shot.

“There’s no doubt that COVID-19 is a much greater risk of this than are any of the vaccines,” said Paul Harrison, a professor of psychiatry at Oxford who co-authored the study.

Story continues below advertisement

Dr. Harrison told a news media briefing on Thursday that the team conducted the research to address the growing controversy over reports that the AstraZeneca vaccine has been linked to cases of CVST, a sometimes fatal condition that occurs when clots form in veins that drain blood from the brain. The Oxford researchers estimated that the mortality rate of people with CVST was 20 per cent.

Denmark recently suspended all use of the AstraZeneca vaccine and several countries, including Canada, have restricted it to older people after reports showed the condition was more common in younger age groups. Regulators in the U.S. have also paused administering the Johnson & Johnson vaccine after six female recipients, all under 50, developed the clots. One woman died.

The Oxford researchers said they hope that their findings will help people better understand the risks of getting COVID-19. “We’ve tried to turn the debate around and put it back on to COVID because even though [CVST] is rare, it appears to be significantly commoner than having the vaccine,” Dr. Harrison said. “We think that’s quite important in helping both regulators and the public understand better the risk-benefit question, which of course is at the heart of what the policy-makers and regulators are trying to do to get it right for the vaccines.”

The researchers used a data set from the TriNetX analytics network, which includes 62 health care organizations in the U.S. comprising 81 million patients.

The study looked at 513,284 cases of COVID-19 and examined how many people developed CVST. They compared that to patients who had the flu and those who had been vaccinated against COVID-19 with the Pfizer vaccine. They drew on data from the European Medicines Agency to compare the findings to cases of clots among people who have received the AstraZeneca vaccine, which has yet to be approved in the U.S.

Of the total number of COVID-19 cases the study examined, 20 people were diagnosed with CVST within two weeks of infection. That equates to 39 out of a million, the researchers said. Of the 20 patients, 10 were under the age of 40, and four people died.

The researchers also looked at 331,503 people who had received the Pfizer vaccine and found that just two had developed CVST, which equates to 4.1 per million. The EMA has also reported 169 cases of the clots out of 34 million vaccinations with the AstraZeneca jab, or five per million.

Story continues below advertisement

The findings concluded that compared with receiving the Pfizer vaccine, the risk of developing CVST from COVID-19 is about 10 times greater. Compared with getting the AstraZeneca vaccine, the risk was roughly eight times higher.

By contrast, none of the people who had the flu developed CVST, and the rate of these blood clots across the entire dataset was 0.41 per million. That meant that the risk of contracting CVST was 100 times higher in people with COVID-19 than in the general population, although the researchers cautioned that the base rate for CVST is difficult to calculate.

The study also examined cases of portal vein thrombosis, or PVT, a type of clotting that develops in vessels that take blood to the liver. Cases of PVT are also rare, but there have been some reports in people who have been vaccinated.

The researchers found 436.4 PVT cases per million in those infected with COVID-19 and 44.9 per million in those who had been vaccinated with the Pfizer shot. The study did not have similar data for the AstraZeneca vaccine.

Health columnist André Picard answers reader questions about COVID-19 variants, how effective the various vaccines are and the impact of on-again, off-again lockdowns. The Globe and Mail

Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a concise summary of the day’s most important headlines. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies